nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—High frequency deafness—Cisplatin—esophageal cancer	0.135	0.135	CcSEcCtD
Tobramycin—Ocular toxicity—Cisplatin—esophageal cancer	0.0479	0.0479	CcSEcCtD
Tobramycin—Ototoxicity—Cisplatin—esophageal cancer	0.0323	0.0323	CcSEcCtD
Tobramycin—Blood calcium decreased—Capecitabine—esophageal cancer	0.0211	0.0211	CcSEcCtD
Tobramycin—Nephrotoxicity—Cisplatin—esophageal cancer	0.0204	0.0204	CcSEcCtD
Tobramycin—Punctate keratitis—Capecitabine—esophageal cancer	0.0189	0.0189	CcSEcCtD
Tobramycin—Tonsillitis—Capecitabine—esophageal cancer	0.0189	0.0189	CcSEcCtD
Tobramycin—Neurotoxicity—Cisplatin—esophageal cancer	0.0167	0.0167	CcSEcCtD
Tobramycin—Ocular discomfort—Methotrexate—esophageal cancer	0.0157	0.0157	CcSEcCtD
Tobramycin—Lower respiratory tract infection—Capecitabine—esophageal cancer	0.014	0.014	CcSEcCtD
Tobramycin—Neurotoxicity—Capecitabine—esophageal cancer	0.0123	0.0123	CcSEcCtD
Tobramycin—Rales—Capecitabine—esophageal cancer	0.0117	0.0117	CcSEcCtD
Tobramycin—Nephropathy toxic—Cisplatin—esophageal cancer	0.0113	0.0113	CcSEcCtD
Tobramycin—Hypophosphataemia—Cisplatin—esophageal cancer	0.0112	0.0112	CcSEcCtD
Tobramycin—Serum creatinine increased—Cisplatin—esophageal cancer	0.0105	0.0105	CcSEcCtD
Tobramycin—Neurotoxicity—Methotrexate—esophageal cancer	0.00918	0.00918	CcSEcCtD
Tobramycin—Rales—Methotrexate—esophageal cancer	0.00867	0.00867	CcSEcCtD
Tobramycin—Leukoderma—Methotrexate—esophageal cancer	0.00837	0.00837	CcSEcCtD
Tobramycin—Platelet count decreased—Capecitabine—esophageal cancer	0.00804	0.00804	CcSEcCtD
Tobramycin—Serum creatinine increased—Capecitabine—esophageal cancer	0.00777	0.00777	CcSEcCtD
Tobramycin—Hypomagnesaemia—Capecitabine—esophageal cancer	0.00752	0.00752	CcSEcCtD
Tobramycin—Keratitis—Capecitabine—esophageal cancer	0.00737	0.00737	CcSEcCtD
Tobramycin—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.00708	0.00708	CcSEcCtD
Tobramycin—Laryngeal pain—Capecitabine—esophageal cancer	0.00701	0.00701	CcSEcCtD
Tobramycin—Hearing impaired—Cisplatin—esophageal cancer	0.00681	0.00681	CcSEcCtD
Tobramycin—Pain—Carboplatin—esophageal cancer	0.00674	0.00674	CcSEcCtD
Tobramycin—Laryngitis—Capecitabine—esophageal cancer	0.00663	0.00663	CcSEcCtD
Tobramycin—Haemoptysis—Capecitabine—esophageal cancer	0.00646	0.00646	CcSEcCtD
Tobramycin—Wheezing—Cisplatin—esophageal cancer	0.0063	0.0063	CcSEcCtD
Tobramycin—Body temperature increased—Carboplatin—esophageal cancer	0.00623	0.00623	CcSEcCtD
Tobramycin—Injection site pain—Capecitabine—esophageal cancer	0.00585	0.00585	CcSEcCtD
Tobramycin—Dysphonia—Capecitabine—esophageal cancer	0.00581	0.00581	CcSEcCtD
Tobramycin—Eye irritation—Capecitabine—esophageal cancer	0.0056	0.0056	CcSEcCtD
Tobramycin—Proteinuria—Capecitabine—esophageal cancer	0.00544	0.00544	CcSEcCtD
Tobramycin—Chest discomfort—Capecitabine—esophageal cancer	0.0054	0.0054	CcSEcCtD
Tobramycin—Protein urine present—Capecitabine—esophageal cancer	0.00536	0.00536	CcSEcCtD
Tobramycin—Deafness—Cisplatin—esophageal cancer	0.00526	0.00526	CcSEcCtD
Tobramycin—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00526	0.00526	CcSEcCtD
Tobramycin—Hypocalcaemia—Capecitabine—esophageal cancer	0.00522	0.00522	CcSEcCtD
Tobramycin—Lacrimation increased—Capecitabine—esophageal cancer	0.00519	0.00519	CcSEcCtD
Tobramycin—Nasal congestion—Cisplatin—esophageal cancer	0.00517	0.00517	CcSEcCtD
Tobramycin—Renal failure acute—Cisplatin—esophageal cancer	0.0051	0.0051	CcSEcCtD
Tobramycin—Blood bilirubin increased—Capecitabine—esophageal cancer	0.00505	0.00505	CcSEcCtD
Tobramycin—Lung disorder—Methotrexate—esophageal cancer	0.00503	0.00503	CcSEcCtD
Tobramycin—Hearing impaired—Capecitabine—esophageal cancer	0.00502	0.00502	CcSEcCtD
Tobramycin—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00478	0.00478	CcSEcCtD
Tobramycin—Dry eye—Capecitabine—esophageal cancer	0.00441	0.00441	CcSEcCtD
Tobramycin—Blood creatinine increased—Cisplatin—esophageal cancer	0.00441	0.00441	CcSEcCtD
Tobramycin—Dehydration—Cisplatin—esophageal cancer	0.00438	0.00438	CcSEcCtD
Tobramycin—Hypokalaemia—Cisplatin—esophageal cancer	0.00428	0.00428	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00424	0.00424	CcSEcCtD
Tobramycin—Apnoea—Methotrexate—esophageal cancer	0.0042	0.0042	CcSEcCtD
Tobramycin—Ear pain—Capecitabine—esophageal cancer	0.00407	0.00407	CcSEcCtD
Tobramycin—Proteinuria—Methotrexate—esophageal cancer	0.00405	0.00405	CcSEcCtD
Tobramycin—Thrombophlebitis—Capecitabine—esophageal cancer	0.00401	0.00401	CcSEcCtD
Tobramycin—Protein urine present—Methotrexate—esophageal cancer	0.00399	0.00399	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00399	0.00399	CcSEcCtD
Tobramycin—Bone disorder—Methotrexate—esophageal cancer	0.00394	0.00394	CcSEcCtD
Tobramycin—Swelling—Capecitabine—esophageal cancer	0.00393	0.00393	CcSEcCtD
Tobramycin—Deafness—Capecitabine—esophageal cancer	0.00388	0.00388	CcSEcCtD
Tobramycin—Oliguria—Methotrexate—esophageal cancer	0.00386	0.00386	CcSEcCtD
Tobramycin—Eye pain—Capecitabine—esophageal cancer	0.00384	0.00384	CcSEcCtD
Tobramycin—Renal failure acute—Capecitabine—esophageal cancer	0.00376	0.00376	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.00368	0.00368	CcSEcCtD
Tobramycin—Renal impairment—Capecitabine—esophageal cancer	0.00365	0.00365	CcSEcCtD
Tobramycin—Renal failure—Cisplatin—esophageal cancer	0.00357	0.00357	CcSEcCtD
Tobramycin—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00356	0.00356	CcSEcCtD
Tobramycin—Lethargy—Capecitabine—esophageal cancer	0.00354	0.00354	CcSEcCtD
Tobramycin—Stomatitis—Cisplatin—esophageal cancer	0.00354	0.00354	CcSEcCtD
Tobramycin—Blood creatinine increased—Capecitabine—esophageal cancer	0.00325	0.00325	CcSEcCtD
Tobramycin—Dehydration—Capecitabine—esophageal cancer	0.00323	0.00323	CcSEcCtD
Tobramycin—Urinary tract disorder—Cisplatin—esophageal cancer	0.00322	0.00322	CcSEcCtD
Tobramycin—Connective tissue disorder—Cisplatin—esophageal cancer	0.0032	0.0032	CcSEcCtD
Tobramycin—Urethral disorder—Cisplatin—esophageal cancer	0.00319	0.00319	CcSEcCtD
Tobramycin—Dry skin—Capecitabine—esophageal cancer	0.00318	0.00318	CcSEcCtD
Tobramycin—Hypokalaemia—Capecitabine—esophageal cancer	0.00316	0.00316	CcSEcCtD
Tobramycin—Visual impairment—Cisplatin—esophageal cancer	0.00314	0.00314	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00312	0.00312	CcSEcCtD
Tobramycin—Muscular weakness—Capecitabine—esophageal cancer	0.00306	0.00306	CcSEcCtD
Tobramycin—Eye disorder—Cisplatin—esophageal cancer	0.00304	0.00304	CcSEcCtD
Tobramycin—Tinnitus—Cisplatin—esophageal cancer	0.00304	0.00304	CcSEcCtD
Tobramycin—Asthma—Capecitabine—esophageal cancer	0.003	0.003	CcSEcCtD
Tobramycin—Thrombophlebitis—Methotrexate—esophageal cancer	0.00298	0.00298	CcSEcCtD
Tobramycin—Bronchospasm—Capecitabine—esophageal cancer	0.00295	0.00295	CcSEcCtD
Tobramycin—Immune system disorder—Cisplatin—esophageal cancer	0.00294	0.00294	CcSEcCtD
Tobramycin—Mediastinal disorder—Cisplatin—esophageal cancer	0.00293	0.00293	CcSEcCtD
Tobramycin—Bronchitis—Capecitabine—esophageal cancer	0.00288	0.00288	CcSEcCtD
Tobramycin—Erythema—Cisplatin—esophageal cancer	0.00283	0.00283	CcSEcCtD
Tobramycin—Renal failure acute—Methotrexate—esophageal cancer	0.0028	0.0028	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00279	0.00279	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00274	0.00274	CcSEcCtD
Tobramycin—Weight decreased—Capecitabine—esophageal cancer	0.00271	0.00271	CcSEcCtD
Tobramycin—Infestation NOS—Capecitabine—esophageal cancer	0.00267	0.00267	CcSEcCtD
Tobramycin—Infestation—Capecitabine—esophageal cancer	0.00267	0.00267	CcSEcCtD
Tobramycin—Vision blurred—Cisplatin—esophageal cancer	0.00267	0.00267	CcSEcCtD
Tobramycin—Lethargy—Methotrexate—esophageal cancer	0.00264	0.00264	CcSEcCtD
Tobramycin—Ill-defined disorder—Cisplatin—esophageal cancer	0.00263	0.00263	CcSEcCtD
Tobramycin—Renal failure—Capecitabine—esophageal cancer	0.00263	0.00263	CcSEcCtD
Tobramycin—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00262	0.00262	CcSEcCtD
Tobramycin—Anaemia—Cisplatin—esophageal cancer	0.00262	0.00262	CcSEcCtD
Tobramycin—Stomatitis—Capecitabine—esophageal cancer	0.00261	0.00261	CcSEcCtD
Tobramycin—Malaise—Cisplatin—esophageal cancer	0.00256	0.00256	CcSEcCtD
Tobramycin—Leukopenia—Cisplatin—esophageal cancer	0.00254	0.00254	CcSEcCtD
Tobramycin—Epistaxis—Capecitabine—esophageal cancer	0.00252	0.00252	CcSEcCtD
Tobramycin—Agranulocytosis—Capecitabine—esophageal cancer	0.0025	0.0025	CcSEcCtD
Tobramycin—Myalgia—Cisplatin—esophageal cancer	0.00241	0.00241	CcSEcCtD
Tobramycin—Rhinitis—Capecitabine—esophageal cancer	0.00241	0.00241	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.0024	0.0024	CcSEcCtD
Tobramycin—Discomfort—Cisplatin—esophageal cancer	0.00238	0.00238	CcSEcCtD
Tobramycin—Pharyngitis—Capecitabine—esophageal cancer	0.00238	0.00238	CcSEcCtD
Tobramycin—Urinary tract disorder—Capecitabine—esophageal cancer	0.00237	0.00237	CcSEcCtD
Tobramycin—Connective tissue disorder—Capecitabine—esophageal cancer	0.00236	0.00236	CcSEcCtD
Tobramycin—Urethral disorder—Capecitabine—esophageal cancer	0.00235	0.00235	CcSEcCtD
Tobramycin—Anaphylactic shock—Cisplatin—esophageal cancer	0.00231	0.00231	CcSEcCtD
Tobramycin—Visual impairment—Capecitabine—esophageal cancer	0.00231	0.00231	CcSEcCtD
Tobramycin—Nervous system disorder—Cisplatin—esophageal cancer	0.00227	0.00227	CcSEcCtD
Tobramycin—Thrombocytopenia—Cisplatin—esophageal cancer	0.00226	0.00226	CcSEcCtD
Tobramycin—Skin disorder—Cisplatin—esophageal cancer	0.00225	0.00225	CcSEcCtD
Tobramycin—Eye disorder—Capecitabine—esophageal cancer	0.00224	0.00224	CcSEcCtD
Tobramycin—Tinnitus—Capecitabine—esophageal cancer	0.00224	0.00224	CcSEcCtD
Tobramycin—Asthma—Methotrexate—esophageal cancer	0.00223	0.00223	CcSEcCtD
Tobramycin—Eosinophilia—Methotrexate—esophageal cancer	0.00221	0.00221	CcSEcCtD
Tobramycin—Anorexia—Cisplatin—esophageal cancer	0.00221	0.00221	CcSEcCtD
Tobramycin—Angiopathy—Capecitabine—esophageal cancer	0.00218	0.00218	CcSEcCtD
Tobramycin—Immune system disorder—Capecitabine—esophageal cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Mediastinal disorder—Capecitabine—esophageal cancer	0.00216	0.00216	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00211	0.00211	CcSEcCtD
Tobramycin—Erythema—Capecitabine—esophageal cancer	0.00209	0.00209	CcSEcCtD
Tobramycin—Paraesthesia—Cisplatin—esophageal cancer	0.00208	0.00208	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00207	0.00207	CcSEcCtD
Tobramycin—Dyspnoea—Cisplatin—esophageal cancer	0.00206	0.00206	CcSEcCtD
Tobramycin—Dysgeusia—Capecitabine—esophageal cancer	0.00205	0.00205	CcSEcCtD
Tobramycin—Back pain—Capecitabine—esophageal cancer	0.00202	0.00202	CcSEcCtD
Tobramycin—Decreased appetite—Cisplatin—esophageal cancer	0.00201	0.00201	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.002	0.002	CcSEcCtD
Tobramycin—Infestation NOS—Methotrexate—esophageal cancer	0.00199	0.00199	CcSEcCtD
Tobramycin—Infestation—Methotrexate—esophageal cancer	0.00199	0.00199	CcSEcCtD
Tobramycin—Pain—Cisplatin—esophageal cancer	0.00198	0.00198	CcSEcCtD
Tobramycin—Vision blurred—Capecitabine—esophageal cancer	0.00197	0.00197	CcSEcCtD
Tobramycin—Renal failure—Methotrexate—esophageal cancer	0.00196	0.00196	CcSEcCtD
Tobramycin—Stomatitis—Methotrexate—esophageal cancer	0.00194	0.00194	CcSEcCtD
Tobramycin—Ill-defined disorder—Capecitabine—esophageal cancer	0.00194	0.00194	CcSEcCtD
Tobramycin—Anaemia—Capecitabine—esophageal cancer	0.00193	0.00193	CcSEcCtD
Tobramycin—Feeling abnormal—Cisplatin—esophageal cancer	0.00191	0.00191	CcSEcCtD
Tobramycin—Malaise—Capecitabine—esophageal cancer	0.00188	0.00188	CcSEcCtD
Tobramycin—Epistaxis—Methotrexate—esophageal cancer	0.00188	0.00188	CcSEcCtD
Tobramycin—Vertigo—Capecitabine—esophageal cancer	0.00188	0.00188	CcSEcCtD
Tobramycin—Leukopenia—Capecitabine—esophageal cancer	0.00187	0.00187	CcSEcCtD
Tobramycin—Agranulocytosis—Methotrexate—esophageal cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Body temperature increased—Cisplatin—esophageal cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Cough—Capecitabine—esophageal cancer	0.00182	0.00182	CcSEcCtD
Tobramycin—Myalgia—Capecitabine—esophageal cancer	0.00178	0.00178	CcSEcCtD
Tobramycin—Chest pain—Capecitabine—esophageal cancer	0.00178	0.00178	CcSEcCtD
Tobramycin—Pharyngitis—Methotrexate—esophageal cancer	0.00177	0.00177	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00177	0.00177	CcSEcCtD
Tobramycin—Urinary tract disorder—Methotrexate—esophageal cancer	0.00176	0.00176	CcSEcCtD
Tobramycin—Discomfort—Capecitabine—esophageal cancer	0.00176	0.00176	CcSEcCtD
Tobramycin—Urethral disorder—Methotrexate—esophageal cancer	0.00175	0.00175	CcSEcCtD
Tobramycin—Visual impairment—Methotrexate—esophageal cancer	0.00172	0.00172	CcSEcCtD
Tobramycin—Confusional state—Capecitabine—esophageal cancer	0.00172	0.00172	CcSEcCtD
Tobramycin—Hypersensitivity—Cisplatin—esophageal cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Nervous system disorder—Capecitabine—esophageal cancer	0.00167	0.00167	CcSEcCtD
Tobramycin—Eye disorder—Methotrexate—esophageal cancer	0.00167	0.00167	CcSEcCtD
Tobramycin—Thrombocytopenia—Capecitabine—esophageal cancer	0.00167	0.00167	CcSEcCtD
Tobramycin—Tinnitus—Methotrexate—esophageal cancer	0.00167	0.00167	CcSEcCtD
Tobramycin—Asthenia—Cisplatin—esophageal cancer	0.00166	0.00166	CcSEcCtD
Tobramycin—Skin disorder—Capecitabine—esophageal cancer	0.00166	0.00166	CcSEcCtD
Tobramycin—Anorexia—Capecitabine—esophageal cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Angiopathy—Methotrexate—esophageal cancer	0.00162	0.00162	CcSEcCtD
Tobramycin—Immune system disorder—Methotrexate—esophageal cancer	0.00161	0.00161	CcSEcCtD
Tobramycin—Mediastinal disorder—Methotrexate—esophageal cancer	0.00161	0.00161	CcSEcCtD
Tobramycin—Diarrhoea—Cisplatin—esophageal cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Erythema—Methotrexate—esophageal cancer	0.00156	0.00156	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00155	0.00155	CcSEcCtD
Tobramycin—Paraesthesia—Capecitabine—esophageal cancer	0.00153	0.00153	CcSEcCtD
Tobramycin—Dysgeusia—Methotrexate—esophageal cancer	0.00152	0.00152	CcSEcCtD
Tobramycin—Dyspnoea—Capecitabine—esophageal cancer	0.00152	0.00152	CcSEcCtD
Tobramycin—Back pain—Methotrexate—esophageal cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Decreased appetite—Capecitabine—esophageal cancer	0.00148	0.00148	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Vomiting—Cisplatin—esophageal cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Vision blurred—Methotrexate—esophageal cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Rash—Cisplatin—esophageal cancer	0.00146	0.00146	CcSEcCtD
Tobramycin—Pain—Capecitabine—esophageal cancer	0.00146	0.00146	CcSEcCtD
Tobramycin—Dermatitis—Cisplatin—esophageal cancer	0.00146	0.00146	CcSEcCtD
Tobramycin—Ill-defined disorder—Methotrexate—esophageal cancer	0.00144	0.00144	CcSEcCtD
Tobramycin—Anaemia—Methotrexate—esophageal cancer	0.00144	0.00144	CcSEcCtD
Tobramycin—Feeling abnormal—Capecitabine—esophageal cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Malaise—Methotrexate—esophageal cancer	0.0014	0.0014	CcSEcCtD
Tobramycin—Vertigo—Methotrexate—esophageal cancer	0.0014	0.0014	CcSEcCtD
Tobramycin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00139	0.00139	CcSEcCtD
Tobramycin—Leukopenia—Methotrexate—esophageal cancer	0.00139	0.00139	CcSEcCtD
Tobramycin—Nausea—Cisplatin—esophageal cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Cough—Methotrexate—esophageal cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Urticaria—Capecitabine—esophageal cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Abdominal pain—Capecitabine—esophageal cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Body temperature increased—Capecitabine—esophageal cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Chest pain—Methotrexate—esophageal cancer	0.00132	0.00132	CcSEcCtD
Tobramycin—Myalgia—Methotrexate—esophageal cancer	0.00132	0.00132	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00132	0.00132	CcSEcCtD
Tobramycin—Discomfort—Methotrexate—esophageal cancer	0.00131	0.00131	CcSEcCtD
Tobramycin—Confusional state—Methotrexate—esophageal cancer	0.00128	0.00128	CcSEcCtD
Tobramycin—Anaphylactic shock—Methotrexate—esophageal cancer	0.00127	0.00127	CcSEcCtD
Tobramycin—Hypersensitivity—Capecitabine—esophageal cancer	0.00126	0.00126	CcSEcCtD
Tobramycin—Nervous system disorder—Methotrexate—esophageal cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Thrombocytopenia—Methotrexate—esophageal cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Skin disorder—Methotrexate—esophageal cancer	0.00123	0.00123	CcSEcCtD
Tobramycin—Asthenia—Capecitabine—esophageal cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Anorexia—Methotrexate—esophageal cancer	0.00121	0.00121	CcSEcCtD
Tobramycin—Pruritus—Capecitabine—esophageal cancer	0.00121	0.00121	CcSEcCtD
Tobramycin—Diarrhoea—Capecitabine—esophageal cancer	0.00117	0.00117	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00116	0.00116	CcSEcCtD
Tobramycin—Paraesthesia—Methotrexate—esophageal cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Dyspnoea—Methotrexate—esophageal cancer	0.00113	0.00113	CcSEcCtD
Tobramycin—Dizziness—Capecitabine—esophageal cancer	0.00113	0.00113	CcSEcCtD
Tobramycin—Decreased appetite—Methotrexate—esophageal cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Pain—Methotrexate—esophageal cancer	0.00109	0.00109	CcSEcCtD
Tobramycin—Vomiting—Capecitabine—esophageal cancer	0.00108	0.00108	CcSEcCtD
Tobramycin—Rash—Capecitabine—esophageal cancer	0.00108	0.00108	CcSEcCtD
Tobramycin—Dermatitis—Capecitabine—esophageal cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Headache—Capecitabine—esophageal cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Feeling abnormal—Methotrexate—esophageal cancer	0.00105	0.00105	CcSEcCtD
Tobramycin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Nausea—Capecitabine—esophageal cancer	0.00101	0.00101	CcSEcCtD
Tobramycin—Urticaria—Methotrexate—esophageal cancer	0.00101	0.00101	CcSEcCtD
Tobramycin—Abdominal pain—Methotrexate—esophageal cancer	0.001	0.001	CcSEcCtD
Tobramycin—Body temperature increased—Methotrexate—esophageal cancer	0.001	0.001	CcSEcCtD
Tobramycin—Hypersensitivity—Methotrexate—esophageal cancer	0.000935	0.000935	CcSEcCtD
Tobramycin—Asthenia—Methotrexate—esophageal cancer	0.000911	0.000911	CcSEcCtD
Tobramycin—Pruritus—Methotrexate—esophageal cancer	0.000898	0.000898	CcSEcCtD
Tobramycin—Diarrhoea—Methotrexate—esophageal cancer	0.000869	0.000869	CcSEcCtD
Tobramycin—Dizziness—Methotrexate—esophageal cancer	0.000839	0.000839	CcSEcCtD
Tobramycin—Vomiting—Methotrexate—esophageal cancer	0.000807	0.000807	CcSEcCtD
Tobramycin—Rash—Methotrexate—esophageal cancer	0.0008	0.0008	CcSEcCtD
Tobramycin—Dermatitis—Methotrexate—esophageal cancer	0.0008	0.0008	CcSEcCtD
Tobramycin—Headache—Methotrexate—esophageal cancer	0.000795	0.000795	CcSEcCtD
Tobramycin—Nausea—Methotrexate—esophageal cancer	0.000754	0.000754	CcSEcCtD
